{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:26:09Z","timestamp":1731475569494,"version":"3.28.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.neurot.2024.e00452","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T03:49:17Z","timestamp":1726804157000},"page":"e00452","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies"],"prefix":"10.1016","volume":"21","author":[{"given":"Leo J.Y.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bornali","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres M.","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin","family":"Rahimpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib1","first-page":"1","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A\u00a0novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00452_bib3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A\u00a0biological classification of Huntington's disease: the Integrated Staging System","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00452_bib4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington's disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5214\/ans.0972.7531.210308","article-title":"The mechanism of degeneration of striatal neuronal subtypes in Huntington disease","volume":"21","author":"Rikani","year":"2014","journal-title":"Ann Neurosci"},{"key":"10.1016\/j.neurot.2024.e00452_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fnhum.2016.00317","article-title":"Corticostriatal dysfunction in Huntington's disease: the basics","volume":"10","author":"Bunner","year":"2016","journal-title":"Front Hum Neurosci"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00452_bib7","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00452_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A\u00a0new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin Genet"},{"issue":"2754","key":"10.1016\/j.neurot.2024.e00452_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1126\/science.106.2754.349","article-title":"Stereotaxic apparatus for operations on the human brain","volume":"106","author":"Spiegel","year":"1947","journal-title":"Science."},{"key":"10.1016\/j.neurot.2024.e00452_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.parkreldis.2018.11.023","article-title":"Successful pallidotomy for post-hyperglycemic hemichorea-ballism","volume":"61","author":"De Vloo","year":"2019","journal-title":"Park Relat Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib11","first-page":"53","article-title":"Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease","volume":"76","author":"Laitinen","year":"1992","journal-title":"J\u00a0Neurosurg"},{"issue":"2-4","key":"10.1016\/j.neurot.2024.e00452_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000029606","article-title":"Stereotactic surgery and Parkinson's disease","volume":"70","author":"Narabayashi","year":"1998","journal-title":"Stereotact Funct Neurosurg"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/mds.870120606","article-title":"Globus pallidus internus pallidotomy for generalized dystonia","volume":"12","author":"Lozano","year":"1997","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/1531-8257(200011)15:6<1248::AID-MDS1029>3.0.CO;2-Q","article-title":"Internal globus pallidotomy in dystonia secondary to Huntington's disease","volume":"15","author":"Cubo","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2024.e00452_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-444-53497-2.00006-1","article-title":"Therapeutic stimulation versus ablation","volume":"116","author":"Hariz","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.20183","article-title":"Bilateral globus pallidus stimulation for Huntington's disease","volume":"56","author":"Moro","year":"2004","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000341070","article-title":"Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington's disease","volume":"91","author":"Velez-Lago","year":"2013","journal-title":"Stereotact Funct Neurosurg"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp.2009.202903","article-title":"Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease","volume":"82","author":"Kang","year":"2011","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib19","doi-asserted-by":"crossref","DOI":"10.1227\/01.NEU.0000195068.19801.18","article-title":"Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington's disease: technical case report","volume":"58","author":"Hebb","year":"2006","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib20","first-page":"130","article-title":"Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus","volume":"109","author":"Biolsi","year":"2008","journal-title":"J\u00a0Neurosurg"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/mds.22116","article-title":"GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case","volume":"23","author":"Fasano","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib22","first-page":"114","article-title":"Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study","volume":"121","author":"Gonzalez","year":"2014","journal-title":"J\u00a0Neurosurg"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2003.11.002","article-title":"Can lesions of GPe correct HD deficits?","volume":"186","author":"Reiner","year":"2004","journal-title":"Exp Neurol"},{"issue":"1-2","key":"10.1016\/j.neurot.2024.e00452_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neulet.2006.07.036","article-title":"Motor and cognitive improvement by deep brain stimulation in a transgenic rat model of Huntington's disease","volume":"406","author":"Temel","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2024.e00452_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fneur.2015.00177","article-title":"A\u00a0prospective pilot trial for pallidal deep brain stimulation in Huntington's disease","volume":"6","author":"Wojtecki","year":"2015","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2024.e00452_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2018.02.030","article-title":"Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington's disease","volume":"51","author":"Zittel","year":"2018","journal-title":"Park Relat Disord"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/mds.24959","article-title":"Deep brain stimulation in Huntington's disease: a 4-year follow-up case report","volume":"27","author":"Spielberger","year":"2012","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00452_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0033-1335097","article-title":"Management and outcome of pallidal deep brain stimulation in severe Huntington's disease","volume":"81","author":"Huys","year":"2013","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ner.12098","article-title":"Bilateral globus pallidus stimulation in Westphal variant of huntington disease","volume":"17","author":"Cislaghi","year":"2014","journal-title":"Neuromodulation"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00452_bib30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00702-014-1201-7","article-title":"Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature","volume":"121","author":"Gruber","year":"2014","journal-title":"J\u00a0Neural Transm"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00452_bib31","article-title":"Pallidal deep brain stimulation in the treatment of Huntington's chorea","volume":"3","author":"Loutfi","year":"2014","journal-title":"Brain Disord Ther"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib32","first-page":"290","article-title":"Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns","volume":"263","author":"Delorme","year":"2016","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/14737175.2022.2091988","article-title":"Deep brain stimulation and stereotactic-assisted brain graft injection targeting fronto-striatal circuits for Huntington's disease: an update","volume":"22","author":"Kinfe","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.neurot.2024.e00452_bib34","first-page":"373","article-title":"Pathogenic mechanisms in huntington's disease","volume":"vol. 98","author":"Jones","year":"2011"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neuron.2017.03.023","article-title":"Mutant huntingtin disrupts the nuclear pore complex","volume":"94","author":"Grima","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00452_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.conb.2015.01.020","article-title":"Corticostriatal synaptic adaptations in Huntington's disease","volume":"33","author":"Plotkin","year":"2015","journal-title":"Curr Opin Neurobiol"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00452_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10063","key":"10.1016\/j.neurot.2024.e00452_bib41","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.neurot.2024.e00452_bib42","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.neurot.2024.e00452_bib43","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"10.1016\/j.neurot.2024.e00452_bib45","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest huntington's disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/mds.28359","article-title":"Hydrocephalus complicating intrathecal antisense oligonucleotide therapy for huntington's disease","volume":"36","author":"Stoker","year":"2021","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2024.e00452_bib47","first-page":"A94","article-title":"J02 Quantitative analyses of pooled tominersen clinical data to support dose selection (rationale) for the new phase II study","volume":"93","author":"Yamamoto","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs in Huntingtin may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr Biol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/genbio.2021.0012","article-title":"Suppression of somatic expansion as a novel therapeutic approach for huntington disease and other repeat expansion disorders","volume":"1","author":"Antonijevic","year":"2022","journal-title":"GEN Biotechnology"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib50","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.031930","article-title":"The central role of DNA damage and repair in CAG repeat diseases","volume":"11","author":"Massey","year":"2018","journal-title":"Dis Model Mech"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib52","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington's disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol Ther: The Journal of the American Society of Gene Therapy"},{"issue":"43","key":"10.1016\/j.neurot.2024.e00452_bib53","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.neurot.2024.e00452_bib54","article-title":"An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6\/2 animal model","volume":"2016","author":"Amaro","year":"2016","journal-title":"J\u00a0Neurodegener Dis"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00452_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41551-021-00760-7","article-title":"CRISPR-based diagnostics","volume":"5","author":"Kaminski","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib56","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nbt.3659","article-title":"Applications of CRISPR technologies in research and beyond","volume":"34","author":"Barrangou","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"6481","key":"10.1016\/j.neurot.2024.e00452_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science."},{"issue":"20","key":"10.1016\/j.neurot.2024.e00452_bib58","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00452_bib60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-Mediated genome editing increases lifespan and improves motor deficits in a huntington's disease mouse model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib61","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1038\/s41467-020-17418-8","article-title":"Prediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment","volume":"11","author":"Kang","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib62","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib63","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat Commun"},{"issue":"30","key":"10.1016\/j.neurot.2024.e00452_bib64","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1073\/pnas.0904239106","article-title":"Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration","volume":"106","author":"Cicchetti","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00452_bib65","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1602\/neurorx.1.4.394","article-title":"Cell therapy in huntington's disease","volume":"1","author":"Dunnett","year":"2004","journal-title":"NeuroRx"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib66","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm0698-727","article-title":"Functional integration of striatal allografts in a primate model of Huntington's disease","volume":"4","author":"Kendall","year":"1998","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00452_bib67","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/nm0898-963","article-title":"Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease","volume":"4","author":"Palfi","year":"1998","journal-title":"Nat Med"},{"issue":"1-4","key":"10.1016\/j.neurot.2024.e00452_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000098976","article-title":"Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea","volume":"58","author":"Sramka","year":"1992","journal-title":"Stereotact Funct Neurosurg"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib69","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/096368970000900212","article-title":"Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results","volume":"9","author":"Fink","year":"2000","journal-title":"Cell Transplant"},{"key":"10.1016\/j.neurot.2024.e00452_bib70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/bs.pbr.2016.12.011","article-title":"From open to large-scale randomized cell transplantation trials in Huntington\u2019s disease: lessons from the multicentric intracerebral grafting in Huntington\u2019s disease trial (MIG-HD) and previous pilot studies","volume":"230","author":"Bachoud-L\u00e9vi","year":"2017","journal-title":"Prog Brain Res"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00452_bib71","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/mds.28201","article-title":"Human fetal cell therapy in huntington\u2019s disease: a randomized, multicenter, phase II trial","volume":"35","author":"Bachoud-L\u00e9vi","year":"2020","journal-title":"Mov Disord"},{"issue":"3-4","key":"10.1016\/j.neurot.2024.e00452_bib72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0361-9230(01)00655-4","article-title":"Anterior cingulate cortical transplantation in transgenic Huntington's disease mice","volume":"56","author":"van Dellen","year":"2001","journal-title":"Brain Res Bull"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A\u00a0double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/exnr.1999.7341","article-title":"Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease","volume":"163","author":"Watts","year":"2000","journal-title":"Exp Neurol"},{"issue":"15","key":"10.1016\/j.neurot.2024.e00452_bib75","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1073\/pnas.1532244100","article-title":"Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain","volume":"100","author":"Curtis","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib76","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/stem.1135","article-title":"Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells","volume":"30","author":"Jeon","year":"2012","journal-title":"Stem Cell"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","article-title":"Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells","volume":"11","author":"An","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00452_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12015-013-9441-8","article-title":"Human pluripotent stem cell differentiation into authentic striatal projection neurons","volume":"9","author":"Delli Carri","year":"2013","journal-title":"Stem Cell Rev Rep"},{"issue":"43","key":"10.1016\/j.neurot.2024.e00452_bib79","doi-asserted-by":"crossref","first-page":"16707","DOI":"10.1073\/pnas.0808488105","article-title":"Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats","volume":"105","author":"Aubry","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib80","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/stem.1462","article-title":"Embryonic stem cells neural differentiation qualifies the role of Wnt\/\u03b2-Catenin signals in human telencephalic specification and regionalization","volume":"31","author":"Nicoleau","year":"2013","journal-title":"Stem Cell"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00452_bib81","doi-asserted-by":"crossref","first-page":"E1234","DOI":"10.1073\/pnas.1611473114","article-title":"Differentiation of human te halic progenitor cells into MSNs by inducible\u00a0expression of Gsx2 and Ebf1","volume":"114","author":"Faedo","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00452_bib82","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1242\/dev.117093","article-title":"Activin A directs striatal projection neuron differentiation of human pluripotent stem cells","volume":"142","author":"Arber","year":"2015","journal-title":"Development"},{"key":"10.1016\/j.neurot.2024.e00452_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1183","article-title":"Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice","volume":"2","author":"Im","year":"2010","journal-title":"PLoS Curr"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00452_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022924","article-title":"Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in huntington's disease mouse models","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1523\/JNEUROSCI.4846-11.2012","article-title":"Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease","volume":"32","author":"Kwan","year":"2012","journal-title":"J\u00a0Neurosci"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib86","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/stem.1508","article-title":"Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease","volume":"32","author":"Rossignol","year":"2014","journal-title":"Stem Cell"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbr.2010.05.023","article-title":"Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease","volume":"214","author":"Dey","year":"2010","journal-title":"Behav Brain Res"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib88","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2016.12","article-title":"Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in huntington's disease mouse models","volume":"24","author":"Pollock","year":"2016","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib89","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ana.21788","article-title":"Slowed progression in models of Huntington disease by adipose stem cell transplantation","volume":"66","author":"Lee","year":"2009","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009347","article-title":"Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for huntington's disease","volume":"5","author":"Snyder","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib91","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: an update","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib92","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4103\/1673-5374.182682","article-title":"Clinical trial perspective for adult and juvenile Huntington's disease using genetically-engineered mesenchymal stem cells","volume":"11","author":"Deng","year":"2016","journal-title":"Neural Regen Res"},{"issue":"16 suppl ment","key":"10.1016\/j.neurot.2024.e00452_bib93","article-title":"PRE-CELL: clinical and novel biomarker measures of disease progression in a lead-in-observational study for a planned phase 1 trial of genetically-modified mesenchymal stem cells over-expressing BDNF in patients with Huntington's disease (S25.004)","volume":"86","author":"Wheelock","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00452_bib94","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.tics.2013.09.016","article-title":"Functional connectomics from resting-state fMRI","volume":"17","author":"Smith","year":"2013","journal-title":"Trends Cognit Sci"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib95","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/brain\/awaa395","article-title":"Untangling the association of amyloid-\u03b2 and tau with synaptic and axonal loss in Alzheimer's disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib96","first-page":"49","article-title":"The significance of the default mode network (dmn) in neurological and neuropsychiatric disorders: a review","volume":"89","author":"Mohan","year":"2016","journal-title":"Yale J Biol Med"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2101","article-title":"Characterizing resting-state networks in Parkinson's disease: a multi-aspect functional connectivity study","volume":"11","author":"Ghasemi","year":"2021","journal-title":"Brain Behav"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib98","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1002\/hbm.22351","article-title":"Altered resting-state connectivity in Huntington's disease","volume":"35","author":"Werner","year":"2014","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.neurot.2024.e00452_bib99","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.nicl.2018.03.013","article-title":"Resting-state connectivity in neurodegenerative disorders: is there potential for an imaging biomarker?","volume":"18","author":"Hohenfeld","year":"2018","journal-title":"Neuroimage Clin"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/1573405614666181115113400","article-title":"Diffusion tensor imaging in preclinical and human studies of huntington's disease: what have we learned so far?","volume":"15","author":"Gatto","year":"2019","journal-title":"Curr Med Imag Rev"},{"key":"10.1016\/j.neurot.2024.e00452_bib101","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2022.03.002","article-title":"Deep brain stimulation for atypical parkinsonism: a systematic review on efficacy and safety","volume":"96","author":"Artusi","year":"2022","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.neurot.2024.e00452_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.827472","article-title":"The application of deep brain stimulation for progressive supranuclear palsy: a systematic review","volume":"13","author":"Wen","year":"2022","journal-title":"Front Neurol"},{"issue":"23","key":"10.1016\/j.neurot.2024.e00452_bib103","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1212\/WNL.0000000000002741","article-title":"Network localization of hemichorea-hemiballismus","volume":"86","author":"Laganiere","year":"2016","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.neurot.2024.e00452_bib104","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMra1706158","article-title":"Mapping symptoms to brain networks with the human connectome","volume":"379","author":"Fox","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ana.25285","article-title":"Identifying therapeutic targets from spontaneous beneficial brain lesions","volume":"84","author":"Joutsa","year":"2018","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00452_bib106","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.20613","article-title":"Improvement of choreic movements by 1 Hz repetitive transcranial magnetic stimulation in Huntington's disease patients","volume":"58","author":"Brusa","year":"2005","journal-title":"Ann Neurol"},{"issue":"15 suppl ment","key":"10.1016\/j.neurot.2024.e00452_bib107","article-title":"Translation of AMT-130 preclinical data to inform the design of the first FDA-approved human AAV gene therapy clinical trial in adults with early manifest Huntington's disease (4531)","volume":"94","author":"Reilmann","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00452_bib108","unstructured":"Gene therapy AMT-130 shows promising results on several outcomes in phase 1\/2 study of huntington disease [press release]. NeurologyLive2023."},{"issue":"11","key":"10.1016\/j.neurot.2024.e00452_bib109","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/jnnp-2020-322904","article-title":"Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease","volume":"91","author":"Richardson","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1 Suppl Operative","key":"10.1016\/j.neurot.2024.e00452_bib110","first-page":"95","article-title":"An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy","volume":"70","author":"Larson","year":"2012","journal-title":"Neurosurgery"},{"issue":"s2","key":"10.1016\/j.neurot.2024.e00452_bib111","first-page":"S199","article-title":"Improved delivery methods for gene therapy and cell transplantation in Parkinson's disease","volume":"11","author":"Larson","year":"2021","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib112","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","article-title":"Safety of AADC gene therapy for moderately advanced Parkinson disease:\u00a0three-year outcomes from the PD-1101 trial","volume":"98","author":"Christine","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00452_bib113","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01616412.1995.11740334","article-title":"Fetal striatal homotransplantation for Huntington's disease: first two case reports","volume":"17","author":"Madrazo","year":"1995","journal-title":"Neurol Res"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/exnr.1997.6685","article-title":"Safety of intrastriatal neurotransplantation for Huntington's disease patients","volume":"149","author":"Kopyov","year":"1998","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/096368979700600303","article-title":"Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations","volume":"6","author":"Philpott","year":"1997","journal-title":"Cell Transplant"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib116","first-page":"185","article-title":"Huntington's disease clinical trials corner: april 2020","volume":"9","author":"Rodrigues","year":"2020","journal-title":"J\u00a0Huntingtons Dis"},{"key":"10.1016\/j.neurot.2024.e00452_bib117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jocn.2015.11.005","article-title":"Stereotactic catheter placement for Ommaya reservoirs","volume":"27","author":"Kennedy","year":"2016","journal-title":"J\u00a0Clin Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib118","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CND.0000000000000333","article-title":"Delivery of nusinersen through an ommaya reservoir in spinal muscular atrophy","volume":"22","author":"Iannaccone","year":"2021","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib119","first-page":"1083","article-title":"Predicting final lesion characteristics during MR-guided focused ultrasound pallidotomy for treatment of Parkinson's disease","volume":"134","author":"Miller","year":"2020","journal-title":"J\u00a0Neurosurg"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000494736","article-title":"Comparative study of robot-assisted versus conventional frame-based deep brain stimulation\u00a0stereotactic neurosurgery","volume":"96","author":"Neudorfer","year":"2018","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00452_bib121","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/jnnp-2020-323656","article-title":"Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis","volume":"92","author":"Lin","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00452_bib122","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.parkreldis.2015.06.018","article-title":"Pallidal deep brain stimulation in Huntington's disease","volume":"21","author":"Zittel","year":"2015","journal-title":"Park Relat Disord"},{"issue":"24","key":"10.1016\/j.neurot.2024.e00452_bib123","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1212\/01.wnl.0000264504.14301.f5","article-title":"Neural transplantation in Huntington disease: long-term grafts in two patients","volume":"68","author":"Keene","year":"2007","journal-title":"Neurology"},{"issue":"Pt 1","key":"10.1016\/j.neurot.2024.e00452_bib124","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/brain\/awh003","article-title":"Striatal neural grafting improves cortical metabolism in Huntington's disease patients","volume":"127","author":"Gaura","year":"2004","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.58.5.687","article-title":"Bilateral human fetal striatal transplantation in Huntington's disease","volume":"58","author":"Hauser","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00452_bib126","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ana.20564","article-title":"Positron emission tomography after fetal transplantation in Huntington's disease","volume":"58","author":"Furtado","year":"2005","journal-title":"Ann Neurol"},{"issue":"25","key":"10.1016\/j.neurot.2024.e00452_bib127","doi-asserted-by":"crossref","first-page":"13877","DOI":"10.1073\/pnas.97.25.13877","article-title":"Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology","volume":"97","author":"Freeman","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jnnp.73.6.678","article-title":"Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475","volume":"73","author":"Rosser","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00452_bib129","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/jnnp.2007.142380","article-title":"Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease","volume":"79","author":"Reuter","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00452_bib130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neuroscience.2009.02.035","article-title":"Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation","volume":"160","author":"Capetian","year":"2009","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib131","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00452_bib132","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","article-title":"Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00452_bib133","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41536-019-0066-7","article-title":"Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice","volume":"4","author":"Cho","year":"2019","journal-title":"NPJ Regen Med"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00452_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006846","article-title":"Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis","volume":"13","author":"Dietrich","year":"2017","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00452_bib136","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02257483","article-title":"Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat","volume":"20","author":"Ambrose","year":"1994","journal-title":"Somat Cell Mol Genet"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00452_bib137","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/ejhg.2016.74","article-title":"A\u00a0novel neurodevelopmental disorder associated with compound heterozygous variants in the huntingtin gene","volume":"24","author":"Rodan","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"Pt 4","key":"10.1016\/j.neurot.2024.e00452_bib138","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00452_bib139","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T13:23:23Z","timestamp":1731417803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":139,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1878747924001399"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00452","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00452"}}